Biofrontera AG Share Price OTC Markets
Equities
BFRA
US09075G1058
Pharmaceuticals
Sales 2021 | 28.79M 30.78M 2.57B | Sales 2022 | 25.74M 27.52M 2.3B | Capitalization | 97.31M 104M 8.68B |
---|---|---|---|---|---|
Net income 2021 | 38M 40.63M 3.39B | Net income 2022 | -44M -47.05M -3.92B | EV / Sales 2021 | 2.79 x |
Net cash position 2021 | 3.61M 3.86M 322M | Net cash position 2022 | 4.88M 5.21M 435M | EV / Sales 2022 | 3.59 x |
P/E ratio 2021 |
2.18
x | P/E ratio 2022 |
-1.98
x | Employees | 92 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.4% |
Latest transcript on Biofrontera AG
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 12/22/12 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 14/21/14 | |
Director/Board Member | - | 14/21/14 | |
Heikki Lanckriet
BRD | Director/Board Member | 47 | 14/21/14 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |